Wipfli Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Wipfli Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$101K	Buy	+950	New	+$96.4K	0.01%	719

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wipfli Financial Advisors's NBIX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q3 2022: 950 shares worth $101K. The stake represents 0.01% of the portfolio and ranks #719 among its holdings.

466 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

Wipfli Financial Advisors held 950 shares of Neurocrine Biosciences worth $101K as of Q3 2022.
Neurocrine Biosciences was a new Wipfli Financial Advisors position in Q3 2022.
Neurocrine Biosciences made up 0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #719 holding.
466 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.